Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer L Lahti

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Plos Computational Biology|September 5, 2009
Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniproteinJennifer L Lahti, Adam P Silverman, Jennifer R Cochran
Proceedings of the National Academy of Sciences of the United States of America|August 10, 2011
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrinNiv Papo, Adam P Silverman, Jennifer L Lahti, et al.
Journal of Molecular Biology|November 29, 2008
Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinitiesAdam P Silverman, Aron M Levin, Jennifer L Lahti, et al.
Journal of the Royal Society, Interface|May 4, 2012
Bioinformatics and variability in drug response: a protein structural perspectiveJennifer L Lahti, Grace W Tang, Emidio Capriotti, et al.
FEBS Letters|March 29, 2011
Engineered epidermal growth factor mutants with faster binding on-rates correlate with enhanced receptor activationJennifer L Lahti, Bertrand H Lui, Stayce E Beck, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Plos Computational Biology|September 5, 2009
Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniproteinJennifer L Lahti, Adam P Silverman, Jennifer R Cochran
Proceedings of the National Academy of Sciences of the United States of America|August 10, 2011
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrinNiv Papo, Adam P Silverman, Jennifer L Lahti, et al.
Journal of Molecular Biology|November 29, 2008
Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinitiesAdam P Silverman, Aron M Levin, Jennifer L Lahti, et al.
Journal of the Royal Society, Interface|May 4, 2012
Bioinformatics and variability in drug response: a protein structural perspectiveJennifer L Lahti, Grace W Tang, Emidio Capriotti, et al.
FEBS Letters|March 29, 2011
Engineered epidermal growth factor mutants with faster binding on-rates correlate with enhanced receptor activationJennifer L Lahti, Bertrand H Lui, Stayce E Beck, et al.
Pageof 1